 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- DK210 / Deka BioSci
Safety and activity of Diakine DK2 10 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial. (Hall A; Poster Bd #: 63) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2986;
P1
These data suggest the EGFR targeted balanced combination of IL-2 with IL-10 improves safety and increases potency of anti-tumor function by dissociating CRS from T cell activation. Further exploration of DK2 10 (EGFR) in RCC and NSCLC as monotherapy and in combination is planned.
- || DK210 / Deka BioSci
Biomarker, Trial completion date, Trial primary completion date, IO biomarker, Metastases: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov) - Dec 15, 2023
P1, N=60, Recruiting, Sponsor: DEKA Biosciences
- DK210 / Deka BioSci
DEKA-1 a dose-finding Phase 1 trial: observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors failing systemic therapy (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1086;
P1
Preliminary human data shows an encouraging safety and efficiency profile. The dose-escalation study is expected to be completed by the end of this year (NCT05704985).
- DK210 / Deka BioSci
DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2291;
P1
Key eligibility criteria include: 1) confirmed progressive disease on at least one line of systemic treatment, 2) EGFR overexpression or amplification documented in histology reports, 3) at least a 4 week or 5 half-lives window since last treatment, and 4) excluding subjects with long QT syndrome, multiple myeloma, multiple sclerosis, myasthenia gravis or uncontrolled infectious, psychiatric, neurologic, or cancer disease. Plasma and tissue samples will be investigated for pharmacodynamic and predictive biomarkers and genetic signatures associated with IFN-gamma secretion, aiming to select subjects for treatment in phase 2.
- |||| DK210 / Deka BioSci
Clinical, PK/PD data: A first-in-human study is assessing the safety, efficacy, and pharmacokinetics of #DK210 for patients with EGFR-expressing solid tumors. @AlexSpiraMDPhD @VCSpecialists Read more in @TargetedOnc: https://t.co/IhcjGLJ16S #MedTwitter #OncTwitter (Twitter) - May 16, 2023
- ||| DK210 / Deka BioSci
Biomarker, Enrollment open, IO biomarker, Metastases: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov) - Feb 21, 2023
P1, N=60, Recruiting, Sponsor: DEKA Biosciences
Plasma and tissue samples will be investigated for pharmacodynamic and predictive biomarkers and genetic signatures associated with IFN-gamma secretion, aiming to select subjects for treatment in phase 2. Not yet recruiting --> Recruiting
- || DK2-10 / Deka BioSci
FDA event, NDA: #DekaBiosciences Receives #FDA Clearance of #DK210 (#EGFR) Investigational #NewDrugApplication https://t.co/eAt9LFN1db (Twitter) - Jan 31, 2023
- | DK210 / Deka BioSci
Biomarker, New P1 trial, IO biomarker, Metastases: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov) - Jan 30, 2023
P1, N=60, Not yet recruiting, Sponsor: DEKA Biosciences